Athira Pharma
18706 North Creek Parkway
Suite 104
Bothell
WA
98011
United States
Tel: 425-620-8501
Website: https://www.athira.com/
Email: Recruiting@athira.com
99 articles with Athira Pharma
-
Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne's calls for a management change.
-
Athira Pharma Doses First Subject in Phase 1 Clinical Trial of HGF/MET Positive Modulator, ATH-1020, an Orally Available Small Molecule for Neuropsychiatric Conditions
4/4/2022
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced that the first subject has been dosed in a Phase 1 clinical trial investigating ATH-1020, an orally available, brain-penetrant small molecule for neuropsychiatric conditions.
-
Athira Pharma Highlights Strong Execution of Strategy and Positioning for the Future
3/30/2022
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, issued the following statement in response to the release from Richard Kayne:
-
BioSpace Movers & Shakers, March 25
3/25/2022
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Athira Pharma Reports Full Year 2021 Financial Results and Provides Clinical Update
3/24/2022
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for the year ended December 31, 2021 and provided a clinical update.
-
Athira Pharma to Participate in Two Upcoming Investor Conferences - Mar 21, 2022
3/21/2022
Athira Pharma, Inc. announced that members of Athira Pharma’s senior management team will participate in the following upcoming investor conferences.
-
Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors
3/21/2022
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors.
-
Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease at the 2022 AD/PD™ Congress
3/20/2022
Athira Pharma, Inc. announced that study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of Athira’s lead development candidate, fosgonimeton in study participants with mild-to-moderate Alzheimer’s disease, were presented in an oral presentation at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Diseases taking place in Barcelona, Spain, and virtually from March 15-20, 2022.
-
Following her ouster as CEO of Athira Pharma, Leen Kawas has co-founded Propel Bio Partners, an equity investment firm focused on helping other life sciences companies.
-
Athira Pharma to Host Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call on March 24, 2022
3/17/2022
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets.
-
Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer’s Disease at AD/PD™ 2022 Congress
3/14/2022
Athira Pharma, Inc. (NASDAQ: ATHA), today announced that an overview and update of the fully enrolled ACT-AD Phase 2 clinical trial with Athira’s lead development candidate fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s disease, will be presented at the International Conference on Alzheimer's & Parkinson Diseases™ 2022, AD/PD™ 2022 hybrid congress.
-
Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
3/2/2022
Athira Pharma, Inc. (NASDAQ: ATHA), today announced preclinical data for the active metabolite of fosgonimeton, a novel small molecule candidate for Alzheimer’s, Parkinson’s disease dementia and Dementia with Lewy bodies, and ATH-1020, an orally available, brain-penetrant small molecule candidate for neuropsychiatric conditions.
-
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
2/22/2022
Athira Pharma, Inc. today announced that preclinical data for the active metabolite of fosgonimeton and Athira’s new oral small molecule, ATH-1020, will be presented in two oral presentations at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting, taking place virtually, Feb. 28 - March 3, 2022.
-
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
2/22/2022
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease.
-
BioSpace Movers & Shakers, Feb. 4
2/4/2022
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers. -
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
1/31/2022
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced the appointment of Grant Pickering to its Board of Directors.
-
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
1/25/2022
Athira Pharma, Inc. today announced that patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor (HGF).
-
BioSpace is marking Martin Luther King, Jr. Day by sharing some of our recent coverage about what the life sciences industry is doing to address racial inequality.
-
Athira Pharma Provides 2022 Pipeline Outlook
1/5/2022
Topline data from ACT-AD Phase 2 Alzheimer’s disease study in 2Q22 LIFT-AD Phase 3 Alzheimer’s disease study sample size increased to strengthen statistical power of co-key secondary endpoints and enhance the potential for a single pivotal clinical study.
-
From the continuing fight against COVID-19 to new companies emerging in exciting therapeutic areas to the people who mattered most, here’s a look at just some of the biggest successes, most dramatic flops – and a few that fall somewhere in between.